This trader lost a lot of money by shorting KaloBios Pharmaceuticals Inc, which went up on the news that Martin Shkreli had taken an ownership stake in them.<p>You may remember Martin Shkreli having been in the news recently for a different reason: he&#x27;s the hedge fund manager who bought the exclusive right to manufacture Daraprim, and raised its price from $13.50&#x2F;tablet to $750&#x2F;tablet, to much outrage. (Daraprim is not subject to patent, but only one manufacturer is allowed to sell it in the United States due to the combination of a small market and regulatory dysfunction at the FDA.)